Liang Shuang, Cai Guang-Yan, Duan Zhi-Yu, Liu Shu-Wen, Wu Jie, Lv Yang, Hou Kai, Li Zuo-Xiang, Zhang Xue-Guang, Chen Xiang-Mei
Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, 28 Fuxing Road, Beijing, 100853, China.
BMC Nephrol. 2017 Feb 15;18(1):63. doi: 10.1186/s12882-017-0482-0.
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. The clinical spectrum of IgAN varies from minor urinary abnormalities to rapidly progressive renal failure. Evaluation of the disease by repeated renal biopsy is not practical due to its invasive procedure. Urinary sediment miRNAs promise to serve as non-invasive biomarkers to assess kidney injury of IgAN.
Fifty two biopsy-proven IgAN patients and twenty five healthy controls were enrolled in the study. Urinary sediment miRNAs were extracted. Expressions of miR-34a, miR-205, miR-21, miR-146a and miR-155 were quantified by real-time quantitative polymerase chain reaction (RT-QPCR). The receiver operating characteristic (ROC) curve was used to investigate the value of the miRNAs for predicting diagnosis of IgAN and evaluating histopathological injury. The patients were treated according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines and followed up. The roles of miRNAs in reflecting therapeutic efficacy and disease progression were analyzed.
The levels of some urinary sediment miRNAs, especially baseline miR-21 and miR-205, may be used as potential prognostic markers for evaluating the tubulointerstitial damage of IgAN. Furthermore, baseline levels of urinary miRNAs may be predictors of therapeutic efficacy and disease progression.
免疫球蛋白A肾病(IgAN)是全球最常见的肾小球肾炎。IgAN的临床谱从轻微的尿液异常到快速进展的肾衰竭不等。由于其侵入性操作,通过重复肾活检评估该疾病并不实用。尿沉渣微小RNA有望作为评估IgAN肾损伤的非侵入性生物标志物。
本研究纳入了52例经活检证实的IgAN患者和25例健康对照。提取尿沉渣微小RNA。通过实时定量聚合酶链反应(RT-QPCR)对miR-34a、miR-205、miR-21、miR-146a和miR-155的表达进行定量。采用受试者工作特征(ROC)曲线研究这些微小RNA在预测IgAN诊断和评估组织病理学损伤方面的价值。患者按照肾脏病改善全球预后(KDIGO)指南进行治疗并随访。分析了微小RNA在反映治疗效果和疾病进展中的作用。
一些尿沉渣微小RNA的水平,尤其是基线miR-21和miR-205,可能作为评估IgAN肾小管间质损伤的潜在预后标志物。此外,尿微小RNA的基线水平可能是治疗效果和疾病进展的预测指标。